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Abstract
Background: The 5000 randomised controlled trials (RCTs) in the Cochrane Schizophrenia
Group's database affords an opportunity to research for variables related to the differences
between nations of their output of schizophrenia trials.
Methods: Ecological study – investigating the relationship between four economic/demographic
variables and number of schizophrenia RCTs per country. The variable with closest correlation was
used to predict the expected number of studies.
Results: GDP closely correlated with schizophrenia trial output, with 76% of the total variation
about the Y explained by the regression line (r = 0.87, 95% CI 0.79 to 0.92, r2 = 0.76). Many
countries have a strong tradition of schizophrenia trials, exceeding their predicted output. All
nations with no identified trial output had GDPs that predicted zero trial activity. Several nations
with relatively small GDPs are, nevertheless, highly productive of trials. Some wealthy countries
seem either not to have produced the expected number of randomised trials or not to have
disseminated them to the English-speaking world.
Conclusions: This hypothesis-generating study could not investigate causal relationships, but
suggests, that for those seeking all relevant studies, expending effort searching the scientific
literature of Germany, Italy, France, Brazil and Japan may be a good investment.
Background
Most randomised trials are produced in the USA. Cer-
tainly, when it comes to trials relevant to the care of peo-
ple with schizophrenia, certain countries have a strong
tradition of trialling, and others have not [1]. This study
investigates whether certain accessible economic and/or
demographic variables are, in some way linked, and can
be predictive of productivity of schizophrenia trials.
Methods
The Cochrane Schizophrenia Group has constructed a
unique collection of reports of randomised controlled tri-
als relevant to schizophrenia [2]. In this collection a single
electronic record is made per study and the multiple refer-
ences/reports/presentations of that study are appended to
that single record. This attempt to decrease the confusion
caused by 'salami' publication is made possible using cus-
tom made specialised reference/study management
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software [3]. A study-based register affords an opportunity
for research. Each study record in the Cochrane Schizo-
phrenia Group's database has been coded for 'country of
origin'. This has had to be defined as the country from
which the first author originates. These data were
extracted from the database (currently 5062 studies), and
the number of trials undertaken in each country
calculated.
Data for gross domestic product (GDP), population,
GDP/Capita, and the number of telephones/100 people,
for all countries, were acquired from the United Nations
website [4]. A second website was used to supplement the
first dataset where gaps were apparent [5]. Both datasets
were figures from 1997. These particular sets of data were
chosen as they are widely accessible, and because the
authors felt they each add some qualities worthy of con-
sideration. GDP is a measure of the sheer wealth of a
nation. The population is the number of people, and, with
a lifetime prevalence of 1% for schizophrenia, it repre-
sents the numbers of people with the illness who live in
the country. GDP/capita is a measure of potential individ-
ual affluence, and number of telephones/100 people, is a
crude estimate of technical development.
Statistical analysis was performed using StatsDirect, Statis-
tical Software [6]. Number of randomised controlled trials
relevant to schizophrenia was correlated against each of
the four economic/demographic variables using simple
and linear regression and Pearson's correlation calculated
(Appendix 1 [see Additional file 1]). Finally, the best-fit
plot was used to interpolate X (economic/demographic
variable of best fit) to Y (calculated number of trials). In
this way it was hoped to estimate the expected output of
schizophrenia trials and compare this to the actual
output.
Results
Of the 5062 studies, 61 (1.21%) were reported in such a
way as to make reliable data extraction of country of ori-
gin impossible. Data extraction for 'country of origin'
defined in the way used in this study has been found to be
reliable in this sample with over 90% agreement [6]. Sim-
ple frequencies of studies by country verify that the USA is
the most productive country of schizophrenia trials (Table
1).
Correlation of the number of trials by each of the four var-
iables is shown in Table 2.
The correlation with GDP was by far the best fit with 76%
of the total variation about the Y explained by the regres-
sion line (log transformation made little difference to the
analysis). Having created the best-fit line, GDP data from
Table 1: Top 10 producers of schizophrenia trials
Country Simple frequency of trials (n)
USA 2363
United Kingdom 669
Canada 275
Germany 256
Japan 113
France 108
Netherlands 104
Sweden 101
Italy 91
China 87
TOTAL 4167
Table 2: Correlation of number of trials (if >0) vs each variable
Variable r 95% CI for r r2
GDP (in million US $) 0.87 0.79 to 0.92 0.76
Population (in thousands) 0.14 -0.11 to 0.38 0.02
GDP/Capita (US $) 0.31 0.06 to 0.52 0.10
Telephones/per 100 inhabitants 0.30 0.06 to 0.52 0.09BMC Psychiatry 2003, 3 http://www.biomedcentral.com/1471-244X/3/18
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every country, whether or not they had been found to pro-
duce a relevant randomised trial, were interpolated to esti-
mate the number of trials predicted by GDP.
The results of these interpolations fell into three distinct
groups: i. Countries for which we had failed to identify
any schizophrenia randomised trials; ii. Countries which
had produced schizophrenia trials and which had a GDP
that predicted trial activity; and finally, iii. Countries for
which the GDPs predicted no trial activity, but that had
undertaken a number of relevant studies.
Countries with no schizophrenia trials
We could not identify any randomised controlled trial
research for people with schizophrenia for 132 (out of
192) countries. All of these countries, with the exception
of Indonesia and Iraq had such low GDPs that trial activ-
ity would not be expected. Indonesia's GDP of $214593
million/year suggests that 25 studies could be expected,
but wide confidence intervals do not exclude zero produc-
tivity (95% CI -16 to 66). The same applied for Iraq's
$149036 million/year, with nine trials predicted but sim-
ilarly wide confidence intervals (95% CI -32 to 51).
Countries productive of schizophrenia trials and also with 
a GDP that predicted trial activity (Table 3)
Finland is far ahead of other nations but numbers of both
actual and expected studies are small. Denmark, however,
is highly productive, as is Sweden, the UK, Canada and the
Netherlands. Using these data, the USA's strong tradition
of undertaking and disseminating trials still is outstand-
ing, but it is the 14th most productive country of schizo-
phrenia trials, according to percent of predicted output.
Table 3: Countries productive of schizophrenia trials ordered by level of productivity
country GDP (mUS $) actual trials > 100 predicted trials % predicted output (95% confidence intervals)
Finland 119834 38 2 1900 (1312–2488)
South Africa 129094 26 5 520 (340–700)
Denmark 161455 79 12 658 (525–792)
Canada 607702 275 118 233 (212–254)
Norway 153362 24 10 240 (167–313)
Greece 118172 15 2 750 (397–1103)
Switzerland 172400 54 15 360 (278–442)
Sweden 227757 101 28 361 (301–421)
Poland 135623 17 6 283 (175–392)
UK 1283335 669 279 240(226–254)
Netherlands 363342 104 60 173(152–196)
Belgium 242508 49 32 153 (128–178)
Austria 206236 33 23 143 (117–170)
USA 7824008 2363 1831 129 (127–132)
Hong Kong 175200 18 16 113 (95–130)
Australia 402787 64 70 91 (85–98)
India 388649 48 66 73 (60–85)
Germany 2089845 256 470 54 (48–61)
Nigeria 142920 4 8 50 (1–99)
China 901981 87 188 46 (36–57)
Turkey 191865 8 19 42 (8–76)
Thailand 153909 4 10 40 (-8–88)
Italy 1145370 91 246 37 (27–47
France 1394124 108 305 35 (26–44)
Spain 531289 32 100 32 (16–48)
Russian Federation 447103 21 80 26 (7–45)
Mexico 402109 13 69 19 (-2–40)
Iran 159391 2 12 17 (-35–68)
Saudi Arabia 134825 1 6 17 (-56–90)
Republic of Korea 442543 13 79 16 (-4–37)
Brazil 806972 21 166 13 (-2–27)
Argentina 323548 6 51 12 (-14–38)
Japan 4192669 113 969 12 (6–18)
Taiwan 308000 4 47 9 (-19–36)BMC Psychiatry 2003, 3 http://www.biomedcentral.com/1471-244X/3/18
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Countries for which GDP predicted no trial activity, but 
which had undertaken relevant studies
Twenty-five countries fell into this category, five of which
produced more than ten studies when none were pre-
dicted by GDP (Table 4).
Discussion
Strengths and limitations
There are several limitations of the datasets used for this
work. The study-based register is in its first draft. Many
papers may be designated as a unique study when they
only represent another report of an already identified ran-
domised trial. Being fully confident of having minimised
undisclosed multiple publications would take some time.
This limitation will result in an overestimate of the
number of studies. The overestimate probably is greatest
for English language reports of industry-sponsored trials,
the great majority of which originate from the USA. A sec-
ond limitation is that the studies are from 1950 to the
present day but the economic/demographic data are from
1997, disregarding the economic/demographic/political
changes over time.
Economies that developed rapidly after World War II,
such as China, Germany, Italy, Japan, Korea and Taiwan
are being judged by the GDP of 1997. This technique
could overestimate the expected output of trials from
countries in which average GDP, or GDP relative to other
countries, would have been considerably less than that of
1997. The crude definition of country of origin as country
from which the first author originates is also a limitation.
The author's origin may not represent the country where
the study took place and we do not know the proportion
of studies for which this accurately reflects where the work
was undertaken. Lastly, the use of GDP is potentially a sur-
rogate measure of one or many causal relationships. It
could be a surrogate for the national investment of the
pharmaceutical industry, the funding and activity of uni-
versities, or/and the degree to which fragmentation of the
family had lead to public concern about the care of people
with schizophrenia. As with any correlation study, this
work is solely hypothesis-generating and not testing.
The USA produces more schizophrenia trials than any
other country (Table 1). When the correlation of the four
economic-demographic variables was undertaken GDP,
whether logged or not, correlated highly with trial output
(whether logged or not). Other variables did not (Table
2). This suggests that trial productivity may neither be a
function of national burden of ill people, nor of individ-
ual prosperity, and not of technological development.
Trial productivity seems more linked with the affluence of
the country, irrespective of population, or technological
development.
Every country that had not produced any randomised tri-
als relevant to schizophrenia had a current GDP that pre-
dicted a study output of zero. The two exceptions
(Indonesia and Iraq) had larger GDPs, but interpolation
of which into the plot still predicted a study output com-
patible with zero (see 95% CIs). Every nation that can
afford it, and many that cannot, undertake schizophrenia
trials.
Table 3, highlights countries with what may be strong tra-
ditions of undertaking and disseminating trials, well
beyond that predicted by GDP. On the other hand, the
plot suggests that Japan, France, Italy, China and Germany
are conducting only between 10–50% of trials predicted
by their high GDPs. One reason for these poor results may
be that those compiling the Cochrane Schizophrenia
Group's database are not identifying relevant trials from
non-Anglophone sources. These figures would suggest
that those seeking as yet unidentified studies should focus
efforts on these countries, where searching is likely to be
fruitful. Investing effort in finding studies from Thailand,
however, where only an additional six studies are pre-
dicted to have not yet been identified, may be considera-
ble effort for little reward. Certainly, researchers in Japan
are acutely aware of the problem of disseminating their
work [7] and have recently created accessible registers to
combat this [8]. The under-representation of schizophre-
nia trials from certain countries could also mean that the
studies do not exist and that the tradition of evaluation of
care for this client group is not strong in these states.
Table 4: Countries with GDPs that predicted no studies, but with >10 trials
Country GDP (million US $) Trials
Israel 92587 83
Czech Republic 52038 78
New Zealand 65291 14
Yugoslavia (Serbia/Montenegro) 17000 10
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Twenty-five countries have a GDP that predicts no schizo-
phrenia trial activity yet some is apparent. Table 4 shows
those states where more than ten studies have been iden-
tified. Israel is out ahead, but with the Czech Republic,
where GDP may be a more accurate representation of the
state's affluence, a close second.
Conclusions
In summary, this hypothesis-generating study finds close
correlation between current GDP figures and a country's
production of schizophrenia trials. It suggests that some
states have been remarkably generous in their commit-
ment to evaluation of care of this group of people. For
other wealthy countries, however, there is a suggestion
that either substantial numbers of randomised trials
remain unidentified, or that there is no great interest in
randomised trials relevant to people with schizophrenia
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